Passa al contenuto
Merck
Tutte le immagini(2)

Documenti fondamentali

Visualizza tutta la documentazione

A3160

Sigma-Aldrich

Acetylsalicylic acid

analytical standard

Sinonimo/i:

2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Formula condensata:
2-(CH3CO2)C6H4CO2H
Numero CAS:
50-78-2
Peso molecolare:
180.16
Beilstein:
779271
Numero CE:
200-064-1
Numero MDL:
MFCD00002430
Codice UNSPSC:
12352106
ID PubChem:
24890723
NACRES:
NA.21

Grado

analytical standard

Livello qualitativo

200

Stato

powder

Confezionamento

vial of 500 mg

tecniche

HPLC: suitable
gas chromatography (GC): suitable

Punto di fusione

134-136 °C (lit.)

applicazioni

forensics and toxicology
pharmaceutical
veterinary

Stringa SMILE

CC(=O)Oc1ccccc1C(O)=O

InChI

1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
BSYNRYMUTXBXSQ-UHFFFAOYSA-N

Informazioni sul gene

human ... ITGA2B(3674) , PTGS1(5742) , PTGS2(5743)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Azioni biochim/fisiol

Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.

Confezionamento

Supplied in amber screw-cap vials

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302

Classi di pericolo

Acute Tox. 4 Oral

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

482.0 °F

Punto d’infiammabilità (°C)

250 °C

Dispositivi di protezione individuale

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
SLCG8819
SLBZ5468
SLBT9582
SLBQ6759V
SLBQ6753V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 5

1 of 5

Aspirin meets USP testing specifications

Sigma-Aldrich

A2093

Aspirin

Acetanilide zone-refined, purified by sublimation, ≥99.95%

Sigma-Aldrich

397237

Acetanilide

Caffeina Sigma Reference Standard, vial of 250 mg

Sigma-Aldrich

C1778

Caffeina

Saccarosio BioUltra, for molecular biology, ≥99.5% (HPLC)

Sigma-Aldrich

84097

Saccarosio

Acetylsalicylic acid-α-13C 99 atom % 13C

Sigma-Aldrich

603287

Acetylsalicylic acid-α-13C

Niels Hulsman et al.
Journal of medicinal chemistry, 50(10), 2424-2431 (2007-04-20)
Hybrid drug 1 (NO-ASA) continues to attract intense research from chemists and biologists alike. It consists of ASA and a -ONO2 group connected through a spacer and is in preclinical development as an antitumor drug. We report that, contrary to
Christina Perneby et al.
Thrombosis and haemostasis, 95(4), 652-658 (2006-04-08)
Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37.5 mg/day for 10 days, 320 mg/day
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
A O Maree et al.
Journal of thrombosis and haemostasis : JTH, 3(10), 2340-2345 (2005-09-10)
Aspirin (acetylsalicylic acid) irreversibly inhibits platelet cyclooxygenase (COX)-1, the enzyme that converts arachidonic acid (AA) to the potent platelet agonist thromboxane (TX) A2. Despite clear benefit from aspirin in patients with cardiovascular disease (CAD), evidence of heterogeneity in the way
Gregg W Stone et al.
Lancet (London, England), 382(9892), 614-623 (2013-07-31)
The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. We aimed to determine the relation between platelet reactivity during dual therapy with aspirin and
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.